Medtronic conducted a post market clinical follow-up (pmcf) survey to seek out potential new risks and assess the performance of medtronic¿s nanocross and rapidcross pta balloons.Survey results received for an vascular surgeon with 14 years¿ experience who was been using the nanocross pta balloons since 2016.The physician has used a total of 15 nanocross balloons, with 11 of these being used in the past 12 months for dilatation of stenoses in the femoral arteries, ilio-femoral arteries, popliteal arteries, infra-popliteal arteries, renal arteries as well as for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula.The nanocross device was also used for stent post-dilatation in the peripheral vasculature.A haemorrhage event is reported as a device related complication during treatment of a fragile vessel where on cannulation submucosal entry made a subintimal bleed.This event was reported to be somewhat concerning.
|